Press Release Summary:
Used for bacterialÂ identification and antimicrobial susceptibility testingÂ (ID/AST), BD Phoenix™ M50 benefits from performance of BD Phoenix 100 system for detecting current and emerging resistances as well as testing capabilities provided by BD Phoenix Emerge AST panel with 136 wells. Integration with multiple other analyzers through BD EpiCenter™ middleware connectivity enables data traceability and security, paperless workflow, and flexible communication capabilities.
Original Press Release:
BD Expands Efforts to Combat Antimicrobial Resistance with New Automated ID/AST System
New BD Phoenix™ M50 System delivers modularity, reliability, affordability and high-quality susceptibility results needed by clinical microbiology laboratories worldwide
FRANKLIN LAKES, N.J. -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of its next generation diagnostic instrument for the rapid identification of bacteria and detection of antimicrobial resistance.
The global health care community is facing unprecedented challenges with the spread of multidrug resistant organisms, and today's clinical microbiology laboratories are under increasing pressure to provide fast and accurate bacterial identification and antimicrobial susceptibility testing (ID/AST) results to influence clinical decision and outcomes.
The new BD Phoenix™ M50 ID/AST system helps deliver the same rapid, accurate and cost-effective testing as the legacy BD Phoenix™ 100, within a smaller footprint. The system is highly reliable and requires no preventative maintenance, thanks to innovative materials and engineering techniques employed during its development. In addition to being robust, the system offers multiple languages, facilitating even broader adoption in laboratories around the world.
The new system benefits from the demonstrated performance of the legacy BD Phoenix 100 system for detecting current and emerging resistances as well as the extended testing capabilities provided by BD Phoenix™ Emerge AST panel with 136 wells.
The BD Phoenix M50 system also offers integration with multiple other analyzers, including the BD BACTEC™ and BD Bruker™ MALDI Biotyper systems, through BD EpiCenter™ middleware connectivity that enables data traceability and security, paperless workflow and flexible communication capabilities to deliver the efficiencies expected by laboratories of all sizes. The BD Phoenix M50 system joins the overall BD diagnostics portfolio to help drive the transformation of microbiology.
"The small footprint of the BD Phoenix M50 system combined with its demonstrated speed, accuracy and efficiency makes the system an attractive solution for microbiology laboratories around the world," said Dave Hickey, president of Diagnostics Systems for BD. "This launch reinforces the engagement of BD to become more relevant in ID/AST and intensifies its support to the fight against antimicrobial resistance."
Visit bd.com/ds for more information.
BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, optimize respiratory care and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 45,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health. For more information on BD, please visit bd.com.
BD Public Relations
Monique N. Dolecki
BD Investor Relations